Q
Qingyu Xiu
Researcher at Second Military Medical University
Publications - 7
Citations - 4296
Qingyu Xiu is an academic researcher from Second Military Medical University. The author has contributed to research in topics: Erlotinib & Lung cancer. The author has an hindex of 7, co-authored 7 publications receiving 3847 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Jifeng Feng,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jie Wang,Songwen Zhou,Shengxiang Ren,Shun Lu,Li Zhang,Chengping Hu,Chunhong Hu,Yi Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You +22 more
TL;DR: It is suggested that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-positive NSCLC, and was associated with more favourable tolerability than standard chemotherapy.
Journal ArticleDOI
Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Ji Feng Feng,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jian Wang,Songwen Zhou,Shengxiang Ren,Shaoyong Lu,Lin Zhang,Chengping Hu,Yi Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You +21 more
TL;DR: The significant OS benefit observed in patients treated with EGFR-TKI emphasises its contribution to improving survival of EGFR mutation-positive advanced non-small-cell lung cancer patients, suggesting that erlotinib should be considered standard first-line treatment of EGfr mutant patients and EGFR -TKI treatment following first- line therapy also brings significant benefits to those patients.
Journal ArticleDOI
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
Gongyan Chen,Ji Feng Feng,Caicun Zhou,Yi-Long Wu,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jian Wang,Songwen Zhou,Shengxiang Ren,Shaoyong Lu,Lei Zhang,C.-P. Hu,Chengping Hu,Y. Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yuling Zhang,Qingyu Xiu,Jun Ma,Changxuan You +22 more
TL;DR: Erlotinib improves QoL compared with standard chemotherapy in the first-line treatment of patients with EGFR mutation-positive advanced NSCLC and updated PFS analyses from this study are described.
Journal ArticleDOI
Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).
Caicun Zhou,Yi-Long Wu,Xiaoqing Liu,Changli Wang,Gongyan Chen,Ji Feng Feng,Shucai Zhang,Jie Wang,Songwen Zhou,Shengxiang Ren,Shun Lu,Li Zhang,Chengping Hu,Yi Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu +19 more
TL;DR: The OPTIMAL study demonstrated significant superiority for E versus GC in terms of progression-free survival (PFS), objective response rate, tolerability and quality of life (QoL) in first-line advanced NSCLC patients with EGFR activating mutations (Act Mut+).
Journal ArticleDOI
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
Yan Sun,Ying Cheng,Xuezhi Hao,Jie Wang,Chengping Hu,Baohui Han,Xiaoqing Liu,Li Zhang,Huiping Wan,Zhongjun Xia,Yunpeng Liu,Wei Li,Mei Hou,Helong Zhang,Qingyu Xiu,Yunzhong Zhu,Jifeng Feng,Shukui Qin,Xiaoyan Luo +18 more
TL;DR: AP therapy demonstrated non-inferiority to EP therapy, prolonging OS for 1.5 months, but this difference was not statistically significant; thus it is proposed as a promising treatment option for ED-SCLC in China.